Lab automation in biotech has moved from liquid-handling convenience to process control: a nonlinear model predictive control system developed by Sartorius researchers increased continuous CHO perfusion production by 68% while holding viable cell density at or above 95%, per a September 23, 2026 report in GEN. That is the field's current shape.
What did the Sartorius controller actually demonstrate?
The system simultaneously controls feed, bleed, and harvest flows in fully continuous biomanufacturing for Chinese hamster ovary cells, per GEN's coverage of the work. It pairs a stabilizing controller with an economic mode that, in the developers' words quoted by GEN, determines optimal operating conditions in real time while explicitly enforcing dynamic process feasibility and biological constraints throughout the perfusion run. The claim that matters to industry readers is the switching: moving between stable operation and economic optimization without controller replacement or reformulation, which is what continuous manufacturing schedules actually require. The results come from the developers' own paper and reported figures; plant-scale replication is the open question, and no independent site data has yet been disclosed.
Why is process control the hard part of lab automation?
Because sample movement was solved before process understanding was. Automated liquid handlers, plate readers, and workcells are mature enough that, as GEN's earlier analysis put it, laboratory automation technologies exist for virtually all stages of drug development — target identification through quality control — eliminating labor-intensive tasks while supporting contamination control, reproducibility, standardization, and data security, per the GEN insight published January 12, 2024. What remains unsolved is the closed loop: having software adjust the biology's operating conditions in real time, under constraints, without an engineer supervising every batch. The Sartorius work targets exactly that gap in perfusion culture, where a wrong control move wastes weeks of a run.
What is the state of the wider market?
Three currents are visible in the public record. First, instrumentation vendors continue to fold analysis into automated lines — spectroscopy-based monitoring that skips calibration model building is reaching bioprocessing floors, shrinking the gap between a sample and a decision. Second, software is becoming the differentiator: protocol design, simulation before hardware runs, and compliance-ready execution environments are where vendors now compete, because the robots themselves are increasingly commodity. Third, the bottleneck has shifted to integration economics; as the GEN analysis noted, automation buys throughput and reproducibility, but the competitive differentiation comes when AI augments the platform to set up and sustain complex workflows. None of these currents is speculative — each is visible in dated vendor disclosures and published process-control work.
What should a professional reader take from the 68% figure?
Its basis, first: a developers' paper on continuous perfusion in CHO cells, reported by a named trade outlet, with the comparison against the uncontrolled baseline run. A 68% production increase in one controlled setting is an engineering result, not a market forecast — it does not price into anyone's capacity until replicated at manufacturing scale across sites. The honest reading of the field in 2026 is that lab automation has stopped being a bench-convenience story and become a process-economics story, and the numbers that count will be published the way this one was: in papers, with controllers, constraints, and cell densities attached.
This article is industry technology coverage for professional readers. It is not medical advice and does not evaluate any product for any laboratory or patient use.
